Cancer cervix
Conditions
Interventions
A group:Patients will receive induction chemotherapy consisted of intravenous paclitaxel 175mg/m^2 day 1 + (Cisplatin 75mg/m^2 day 1 or Carboplatin AUC 5 day 1 according to pt is eligible to cisplati
B group:Patients will receive standard chemoradiotherapy (consisted of weekly cisplatin 40 mg/m2 or Carboplatin AUC 2 for 5 weeks concurrent with External beam radiotherapy) followed by brachytherapy
Sponsors
Sohag university
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1.Age between 18 and 70 years; 2.Clinically staged as IB3–IVA according to the International Federation of Gynecology and Obstetrics (FIGO); 3.Histologically proved squamous cell carcinoma or adenocarcinoma of the uterine cervix; 4.Performance status 0–2 according to Word Health Organization (WHO) criteria; 5.Normal hematological, renal and hepatic function.
Exclusion criteria
Exclusion criteria: 1.Severe systemic or uncontrolled disease (infection, central nervous system, metabolic, etc.) that precluded the use of chemotherapy; 2.Pre-existing high grade neuropathy of any cause; 3.Histologically proved small cell carcinoma, leiomyosarcoma, lymphoma and other histopathologies other than Squamous cell carcinoma & adenocarcinoma; 4.Mental illness; 5.Previous or concomitant malignancies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The clinical response rate at the end of induction chemotherapy;Overall survival rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression free survival;Disease-free survival;Adverse events associated with the treatment; | — |
Countries
Egypt
Contacts
Public ContactAya Mohamed Atya EI Morsy
Sohag university
Outcome results
None listed